Clinical response to sitafloxacin based on the acute rhinosinusitis medical treatment guidelines (adults)

Abstract

In accordance with the treatment algorithm in "Clinical Practice Guideline for Acute Rhinosinusitis 2010", the severity of rhinosinusitis was determined in adult patients. The efficacy and safety was evaluated after administrating sitafloxacin (STFX) to the moderate-to-severe patients. Therapeutic response was determined based on severity scores at the end of treatment. As a result, 100% of the patients (47/47) had "very effective" or "effective" to treatment, showing a high improvement rate. The attending doctor evaluated that 91.5% of the patients (43/47) were cured. Bacterial disappearance rate after treatment was 100% (45/45 strains), but microbial substitution was noted in one case. No noticeable adverse reaction was observed in the patients of the present study. These results suggest that STFX may be a potentially useful drug in adult patients with moderate-to-severe acute rhinosinusitis.